Waldron Private Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.09M | Sell |
4,208
-13
| -0.3% | -$5.76K | 0.07% | 97 |
|
|
2026
Q1 | $1.88M | Buy |
4,221
+37
| +0.9% | +$17.3K | 0.07% | 99 |
|
|
2025
Q4 | $1.9M | Sell |
4,184
-116
| -3% | -$50K | 0.08% | 93 |
|
|
2025
Q3 | $1.68M | Buy |
4,300
+119
| +3% | +$49.7K | 0.07% | 99 |
|
|
2025
Q2 | $1.86M | Sell |
4,181
-15
| -0.4% | -$6.91K | 0.08% | 91 |
|
|
2025
Q1 | $2.03M | Sell |
4,196
-690
| -14% | -$322K | 0.1% | 83 |
|
|
2024
Q4 | $1.97M | Sell |
4,886
-197
| -4% | -$91.3K | 0.08% | 109 |
|
|
2024
Q3 | $2.36M | Buy |
5,083
+78
| +2% | +$37.5K | 0.1% | 96 |
|
|
2024
Q2 | $2.35M | Sell |
5,005
-115
| -2% | -$49.9K | 0.11% | 92 |
|
|
2024
Q1 | $2.14M | Buy |
5,120
+7
| +0.1% | +$2.96K | 0.1% | 96 |
|
|
2023
Q4 | $2.08M | Buy |
5,113
+54
| +1% | +$19.9K | 0.1% | 95 |
|
|
2023
Q3 | $1.76M | Sell |
5,059
-33
| -0.6% | -$11.5K | 0.09% | 103 |
|
|
2023
Q2 | $1.79M | Sell |
5,092
-449
| -8% | -$151K | 0.09% | 104 |
|
|
2023
Q1 | $1.75M | Sell |
5,541
-160
| -3% | -$48K | 0.09% | 116 |
|
|
2022
Q4 | $1.65M | Hold |
5,701
| – | – | 0.1% | 112 |
|
|
2022
Q3 | $1.65M | Buy |
5,701
+101
| +2% | +$29.1K | 0.1% | 112 |
|
|
2022
Q2 | $1.58M | Buy |
5,600
+159
| +3% | +$42.6K | 0.09% | 127 |
|
|
2022
Q1 | $1.42M | Buy |
5,441
+90
| +2% | +$21.4K | 0.07% | 142 |
|
|
2021
Q4 | $1.18M | Sell |
5,351
-204
| -4% | -$39.7K | 0.06% | 156 |
|
|
2021
Q3 | $1.01M | Buy |
5,555
+346
| +7% | +$67.6K | 0.06% | 152 |
|
|
2021
Q2 | $1.05M | Sell |
5,209
-2
| -0% | -$418 | 0.07% | 135 |
|
|
2021
Q1 | $1.12M | Sell |
5,211
-75
| -1% | -$16.5K | 0.08% | 122 |
|
|
2020
Q4 | $1.25M | Sell |
5,286
-17
| -0.3% | -$3.9K | 0.09% | 110 |
|
|
2020
Q3 | $1.44M | Buy |
5,303
+114
| +2% | +$31.5K | 0.12% | 100 |
|
|
2020
Q2 | $1.51M | Sell |
5,189
-233
| -4% | -$63.2K | 0.13% | 88 |
|
|
2020
Q1 | $1.29M | Buy |
5,422
+15
| +0.3% | +$3.44K | 0.14% | 88 |
|
|
2019
Q4 | $1.18M | Hold |
5,407
| – | – | 0.11% | 102 |
|
|
2019
Q3 | $916K | Hold |
5,407
| – | – | 0.09% | 108 |
|
|
2019
Q2 | $991K | Buy |
5,407
+113
| +2% | +$19.8K | 0.11% | 86 |
|
|
2019
Q1 | $973K | Buy |
5,294
+1,581
| +43% | +$292K | 0.11% | 90 |
|
|
2018
Q4 | $615K | Buy |
3,713
+201
| +6% | +$34.8K | 0.09% | 107 |
|
|
2018
Q3 | $676K | Buy |
+3,512
| New | +$625K | 0.13% | 80 |
|
Other funds holding VRTX
Waldron Private Wealth's VRTX Position: Q2 2026 in Review
Waldron Private Wealth reduced its Vertex Pharmaceuticals (VRTX) stake by 0.31% in Q2 2026, selling an estimated $5.76K and leaving 4,208 shares worth $2.09M. The position accounts for 0.07% of the portfolio, ranked #97.
Waldron Private Wealth first reported a position in VRTX in Q3 2018 and has held it in 32 quarters since. The position peaked at $2.36M in Q3 2024. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Waldron Private Wealth held 4,208 shares of Vertex Pharmaceuticals worth $2.09M as of Q2 2026.
- Waldron Private Wealth sold 13 Vertex Pharmaceuticals shares in Q2 2026, an estimated $5.76K.
- Vertex Pharmaceuticals made up 0.07% of Waldron Private Wealth's portfolio in Q2 2026, its #97 holding.
- Waldron Private Wealth first reported a position in Vertex Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
- Waldron Private Wealth's Vertex Pharmaceuticals position peaked at $2.36M in Q3 2024.
- 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Waldron Private Wealth's 13F filing for Q2 2026, filed 20 Jul 2026.